JAK1 signaling in dendritic cells promotes peripheral tolerance in autoimmunity through PD-L1-mediated regulatory T cell induction

Andrea Vogel
Medical University of Vienna
January 1, 2022
Cell Rep
https://pubmed.ncbi.nlm.nih.gov/35196494

This article is currently being updated. View its version on PubMed.

https://pubmed.ncbi.nlm.nih.gov/35196494

Research summary

This study investigates the role of Janus kinase 1 (JAK1) signaling within dendritic cells (DCs) in maintaining peripheral immune tolerance. Using a mouse model with DC-specific deletion of JAK1, researchers observed exacerbated experimental autoimmune encephalomyelitis (EAE), characterized by increased CD4+ T cell proliferation and reduced regulatory T cell (Treg) induction. The findings highlight the importance of JAK1-STAT1 signaling in DCs for upregulating PD-L1 expression, which is crucial for the conversion of naive CD4+ T cells into Tregs and the suppression of autoimmune responses.

Key outcome of the study

JAK1 signaling in DCs is essential for PD-L1 expression and the induction of Tregs, thereby promoting peripheral tolerance and mitigating autoimmune pathology in EAE.

Model

DC-specific JAK1 Knockout mouse model, generated by crossing Jak1^flox/flox mice with CD11c-Cre transgenic mice to achieve targeted deletion of JAK1 in dendritic cells.

TARGET:
JAK1
Janus kinase 1

Keywords

Autoimmunity, Peripheral tolerance, Dendritic cells, Regulatory T cells, PD-L1, JAK-STAT signaling

Technical specifications

Conditional Knockout model, CD11c-Cre, Jak1^flox/flox, Dendritic cell-specific gene deletion

Related products

Catalogue product

KO repository

>2000 conditional Knockout mouse models for target discovery and  confirmation, in vivo compound specificity, MOA, and clinical studies

Customized product

No items found.
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe